Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to test the safety of Pembrolizumab and Temozolomide in
treating recurrent glioblastoma and to characterize the effect of this treatment on the
participants tumor and immune system..